Literature DB >> 19332867

Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma.

Edgar J Rolleman, Jan Weening, Michiel G H Betjes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19332867     DOI: 10.1093/ndt/gfp140

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  6 in total

1.  Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.

Authors:  Daiei Takahashi; Kiyotaka Nagahama; Yukio Tsuura; Hiroyuki Tanaka; Teiichi Tamura
Journal:  Clin Exp Nephrol       Date:  2011-10-01       Impact factor: 2.801

Review 2.  Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function.

Authors:  Łukasz Mielczarek; Anna Brodziak; Paweł Sobczuk; Maciej Kawecki; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-25       Impact factor: 3.333

3.  Development of nephrotic syndrome after administration of sorafenib in a case of metastatic renal cell carcinoma.

Authors:  Yumiko Okuno; Haruki Kume; Chihiro Hosoda; Yukio Homma
Journal:  Case Rep Med       Date:  2011-10-05

Review 4.  Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients.

Authors:  Aleksandra Semeniuk-Wojtaś; Arkadiusz Lubas; Rafał Stec; Cezary Szczylik; Stanisław Niemczyk
Journal:  Int J Mol Sci       Date:  2016-12-09       Impact factor: 5.923

Review 5.  Hypertension in malignancy-an underappreciated problem.

Authors:  Jolanta Małyszko; Maciej Małyszko; Leszek Kozlowski; Klaudia Kozlowska; Jacek Małyszko
Journal:  Oncotarget       Date:  2018-04-17

6.  Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report.

Authors:  Yoshitaka Furuto; Hirotsugu Hashimoto; Akio Namikawa; Haruki Outi; Hiroko Takahashi; Hajime Horiuti; Kazuho Honda; Yuko Shibuya
Journal:  BMC Nephrol       Date:  2018-10-19       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.